

1 **Epidemiology of SARS-CoV-2 Emergence Amidst Community-Acquired Respiratory**

2 **Viruses**

3 Karoline Leuzinger^{1,2}, Tim Roloff^{3,4}, Rainer Gosert¹, Kirstin Sogaard^{3,4}, Klaudia Naegele¹,

4 Katharina Rentsch⁵, Roland Bingisser⁶, Christian H. Nickel⁶, Hans Pargger⁷, Stefano

5 Bassetti⁸, Julia Bielicki⁹, Nina Khanna¹⁰, Sarah Tschudin Sutter¹⁰, Andreas Widmer¹⁰,

6 Vladimira Hinic¹⁴, Manuel Battegay¹⁰, Adrian Egli^{3,4,+}, Hans H. Hirsch^{1,2,10+}

7 + equal contribution

8

9 ¹ Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland

10 ² Transplantation & Clinical Virology, Department Biomedicine, University of Basel, Basel,

11 Switzerland

12 ³ Applied Microbiology Research, Laboratory Medicine, Department Biomedicine, University

13 of Basel, Basel, Switzerland

14 ⁴ Clinical Bacteriology and Mycology, Laboratory Medicine, University Hospital Basel, Basel,

15 Switzerland

16 ⁵ Clinical Chemistry, Laboratory Medicine, University Hospital Basel, Basel, Switzerland

17 ⁶ Emergency Medicine, University Hospital Basel, Basel, Switzerland

18 ⁷ Intensive Care Unit, University Hospital Basel, Basel, Switzerland

19 ⁸ Internal Medicine, University Hospital Basel, Basel, Switzerland

20 ⁹ Pediatric Infectious Diseases & Hospital Epidemiology, University Children Hospital Basel,

21 Basel, Switzerland

22 ¹⁰ Infectious Diseases & Hospital Epidemiology, University Hospital Basel

23

24 **Short Title** Epidemiology of SARS-CoV-2 and CARVs

25

26 **Keywords** COVID-19, respiratory virus, multiplex, nucleic acid testing, co-infection

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **Conflict of interest statement**

28 All authors: none to declare.

29

30 **Funding statement**

31 This work was supported by the Clinical Virology Division and the Clinical Bacteriology and

32 Mycology Division, Laboratory Medicine, University Hospital Basel, Basel, Switzerland, and

33 an appointment grant to HHH, Department Biomedicine, University of Basel, Basel,

34 Switzerland.

35

36 **Corresponding author contact information**

37 Hans H. Hirsch, MD MSc

38 Transplantation & Clinical Virology

39 Department Biomedicine

40 University of Basel

41 Petersplatz 10

42 4009 Basel, Switzerland

43 Phone: +41 61 328 6697

44 Email: hans.hirsch@unibas.ch

45 **Abstract**

46 **Background.** SARS-CoV-2 emerged in China in December 2019 as new cause of severe
47 viral pneumonia (CoVID-19) reaching Europe by late January 2020. We validated the WHO-
48 recommended assay and describe the epidemiology of SARS-CoV-2 and community-
49 acquired respiratory viruses (CARVs).

50 **Methods.** Naso-oropharyngeal swabs (NOPS) from 7663 individuals were prospectively
51 tested by the Basel-S-gene and the WHO-based E-gene-assay (Roche) using Basel-N-
52 gene-assay for confirmation. CARVs were tested in 2394 NOPS by multiplex-NAT, including
53 1816 together with SARS-CoV-2.

54 **Results.** Basel-S-gene and Roche-E-gene-assays were concordant in 7475 cases (97.5%)
55 including 825 (11%) positive samples. In 188 (2.5%) discordant cases, SARS-CoV-2 loads
56 were significantly lower than in concordant positive ones and confirmed in 105 NOPS. Adults
57 were more likely to test positive for SARS-CoV-2, while children were more likely to test
58 CARV-positive. CARV co-infections with SARS-CoV-2 occurred in 1.8%. SARS-CoV-2
59 replaced other CARVs within 3 weeks reaching 48% of all detected respiratory viruses
60 followed by rhino/enterovirus (13%), influenzavirus (12%), coronavirus (9%), respiratory
61 syncytial (6%) and metapneumovirus (6%).

62 **Conclusions.** The differential diagnosis for respiratory infections was broad during the early
63 pandemic, affecting infection control and treatment decisions. We discuss the role of pre-
64 existing immunity and competitive CARV replication for the epidemiology of SARS-CoV-2
65 infection among adults and children.

66

67 **Abstract Word Count: 200**

68 **Background**

69 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in China during
70 winter 2019 as new cause of severe viral pneumonia called coronavirus infectious disease
71 (CoVID)-19 [1, 2]. Since late January 2020, SARS-CoV-2 continues to spread across the
72 world including Europe [1, 3]. By the end of May 2020, the WHO reported more than 5
73 million confirmed SARS-CoV-2 cases, 400 thousand deaths of which approximately one
74 third occurred in Europe [4]. The first case in Switzerland was diagnosed on 25 February
75 2020, reaching peak rates by the end of March before plateauing at approximately 30'000
76 confirmed cases by the end of April 2020 (<https://covid-19-schweiz.bagapps.ch/de-2.html>).
77 Notably, the initial pandemic spread of SARS-CoV-2 occurred in the winter months of the
78 Northern hemisphere, during which several community-acquired respiratory viruses
79 (CARVs) are known to circulate including influenzavirus-A/B, respiratory syncytial virus,
80 metapneumovirus, parainfluenzavirus, and human coronaviruses. Although the progression
81 of SARS-CoV-2 infection to severe lower respiratory tract infectious disease (RTID) is
82 unprecedented, all CARVs are known to significantly contribute to seasonal excess
83 morbidity and mortality in immunocompetent and immunocompromised populations [5]. In
84 fact, CARV-RTID presents clinically as an influenza-like illness defined as at least one
85 respiratory and one systemic symptom/sign such as clogged or runny nasal airways, sore
86 throat, cough, fatigue, fever, myalgia [5], which may be indistinguishable from early stages of
87 SARS-CoV-2 infection [6], while dysgeusia appears to be rather prominent. Thus, a broad
88 diagnostic approach using multiplex nucleic acid testing (NAT) may be important. Notably,
89 the course and impact of SARS-CoV-2 on circulating CARVs has not been fully
90 characterized. Early reports suggested that co-infections with SARS-CoV-2 and other
91 CARVs were rather uncommon in immunocompetent adults [7]. However, a recent study
92 reported co-infection of CARVs and SARS-CoV-2 at rates of 5% including influenzavirus-
93 A/B, respiratory syncytial virus and rhinoviruses [8]. Here, we report on the epidemiology of
94 SARS-CoV-2 infection and other CARVs during the early pandemic peak in Northwestern
95 Switzerland from January 1 until March 29, 2020.

96 **Methods**

97 *Patients and samples*

98 Patients presenting with influenza-like illness to the outpatient department or emergency
99 department of the University Hospital Basel or the University of Basel Children's Hospital
100 were enrolled in this analysis of prospectively collected results on respiratory virus panel
101 and/or SARS-CoV-2 testing between 1. January and 29. March 2020.

102

103 *Clinical samples and total nucleic acid extraction*

104 For sampling, two swabs from the naso- and oropharyngeal sites (NOPS), respectively,
105 were taken and combined into one universal transport medium tube (UTM, Copan). In
106 smaller children, only nasopharyngeal swabs were taken. Total nucleic acids (TNAs) were
107 extracted from the UTM using the MagNA Pure 96 system and the DNA and viral NA small
108 volume kit (Roche Diagnostics, Rotkreuz, Switzerland) or using the Abbott m2000 Realtime
109 System and the Abbott sample preparation system reagent kit (Abbott, Baar, Switzerland).

110

111 *SARS-CoV-2 reverse transcription quantitative nucleic acid testing*

112 TNAs were tested for SARS-CoV-2 RNA using a laboratory-developed reverse transcription
113 quantitative nucleic acid test (RT-QNAT) targeting specific viral sequences of the spike
114 glycoprotein S-gene (Basel-SCoV2-S-111bp; **Supplementary Table 1**) and a commercial
115 RT-QNAT targeting the viral envelope gene (E-gene; Roche). For the Roche assay, the
116 extraction control was included as specified by the manufacturer, while Basel assays were
117 spiked with unrelated nucleic acids. Both assays were run on independent plates in parallel
118 for all NOPS tested. Concordant negative results were interpreted as confirmed, while
119 concordant positive and discordant results were retested with a laboratory-developed RT-
120 QNAT targeting the viral nucleocapsid gene (Basel-SCoV2-N-98bp; **Supplementary Table**
121 **1**). The Roche-E-gene was run on the CFX96 RT-PCR (Bio-Rad Laboratories, Cressier,
122 Switzerland) as specified by the manufacturer. The Basel-SCoV2-S-111bp and Basel-
123 SCoV2-N-98bp used the RT Takyon MMX containing uridine and the uracil-N-glycosylase

124 for amplicon decontamination (Eurogentec, Liège, Belgium), 300 nmoles end concentration
125 of the primers and probe for the Basel-S-gene RT-QNAT, and 900 nmoles end concentration
126 of the primers and 100 nmoles probe for the Basel-SCoV2-N-98bp RT-QNAT
127 (**Supplementary Table 1**). The Basel assays had a reaction volume of 25 µL and 5 µL of
128 extracted TNA run on an ABI7500 Fast Real-Time PCR system (Thermo Fisher Scientific,
129 Massachusetts, United States). The single-step reverse transcription and cycling conditions
130 for the RT-QNATs were 50 °C for 10 min; 95 °C for 5 min; and 45 cycles of 95 °C for 30 s
131 and 60°C for 60 s.

132

133 *Phylogenetic analysis of SARS-CoV-2 genome sequences*

134 SARS-CoV-2 complete genome sequences (N=3323), the S-gene and N-gene sequences
135 were downloaded from the NCBI-GenBank and GISAID database (<https://www.gisaid.org/>;
136 accessed on 20th of April). Sequence alignments were performed with the CLC Genomic
137 Workbench software (version 12; QIAGEN, Hilden, Germany). Divergences were estimated
138 by the Jukes-Cantor method, and neighbor-joining trees were visualized with the CLC
139 Genomic Workbench software. In addition, the frequency of single nucleotide polymorphisms
140 (SNPs) was assessed in the S-gene and N-gene RT-QNAT target regions with the basic
141 variant detection tool of the CLC Genomic Workbench software and a viral reference genome
142 (acc. no. NC_045512; **Supplementary Table 2**) as described previously [9].

143

144 *Biofire Filmarray respiratory panel*

145 The qualitative multiplex NAT respiratory panel used 200 µL of UTM in the Torch system
146 (Biofire Filmarray respiratory 2.0 panel, bioMérieux) covering influenzavirus (IV)-A (A/H1,
147 A/H1-2009, A/H3), IV-B, human respiratory syncytial virus (HRSV)-A/B, adenovirus (HAdV),
148 human metapneumovirus (HMPV), rhinovirus/enterovirus (HRV), parainfluenzavirus (HPIV)
149 1-4 (as separate targets), human coronavirus (HCoV)-NL63, -229E, -OC43, -HKU1, -middle
150 east respiratory syndrome (MERS)-CoV, *Bordetella pertussis*, *B. parapertussis*,
151 *Chlamydophila pneumonia*, and *Mycoplasma pneumoniae*.

152

153 *Statistics and graphical presentations*

154 All statistical data analysis was done in R (<https://www.r-project.org/>), and Prism (version 8;

155 Graphpad Software, CA, USA) was used for data visualization. Statistical comparison of

156 non-parametric data was done using Mann–Whitney U test, and Bonferroni correction was

157 applied for multiple comparisons.

158

159 *Ethics statement*

160 The study was conducted according to good laboratory practice and in accordance with the

161 Declaration of Helsinki and national and institutional standards and was approved by the

162 ethical committee (EKNZ 2020-00769).

163 **Results**

164 To independently evaluate the WHO-recommended assay, we designed two different single
165 step RT-QNAT assays targeting the S-gene and the N-gene. We observed close clustering
166 of the complete SARS-CoV-2 genomes and specifically its S- and N-gene target sequences,
167 clearly separating from the corresponding HCoV genome sequences (**Supplementary**
168 **Figure 1**). We found no insertions or deletions in either target, and only a single SNP in the
169 probe-binding site of the S-gene RT-QNAT in one of 3323 (0.03%) sequences, at a central
170 position not predicted to affect the assay performance (**Supplementary Table 2**).

171

172 To cross-validate the WHO-Roche-E-gene and the Basel-S-gene without reporting delay, we
173 analyzed all submitted NOPS directly in parallel. From 9th until 29th of March 2020 (calendar
174 week 11 to 13), 7663 samples were submitted from 354 (5%) pediatric and 7309 (95%) adult
175 patients (**Table 1**). Most patients had presented to primary care and outpatient clinics (74%),
176 while 26% of cases originated from secondary and tertiary care units including 3% from
177 intensive care (**Table 1**). The Basel-S-gene and the Roche-E-gene RT-QNATs were
178 concordant in 7475 (97.5%) samples, consisting of 6650 (86.8%) negative and 825 (10.7%)
179 positive cases, all of which were independently confirmed by the N-gene assay
180 (**Supplementary Figure 2**). In 188 (2.5%) cases, discordant results were obtained
181 consisting of 170 (2.2%) Basel-S-gene positive/ Roche-E-gene negative, and 18 (0.2%)
182 Basel-S-gene negative/Roche-E-gene positive cases. The N-gene RT-QNAT confirmed
183 102/170 (60%; overall 1.3%) of the former, but only 3 (0.04%) of the latter (**Supplementary**
184 **Figure 2**). Cycle threshold (Ct)-values were significantly lower in these samples, indicating a
185 higher viral load for concordant positive than for discordant results (median, S-gene RT-
186 QNAT: 23.6 vs. 36.8 vs. 37.1; $P < 0.001$; **Figure 1A**). Indeed, 666 (72%) NOPS extracts had
187 SARS-CoV-2 loads of more than 1 million copies (c)/mL UTM in the S-gene RT-QNAT
188 (median 7.2 log₁₀ c/mL, IQR 5.8 – 8.4; **Figure 1B**). Conversely, the Ct-values were
189 significantly higher for discordant results indicating low viral loads (**Figure 1A**). Thus, the
190 Basel-SCoV2-S-111bp had a sensitivity of 99.7% (95% CI: 95% - 100%) and specificity of

191 99.0% (95% CI: 91% - 100%). Taken together, 930 (12.1%) SARS-CoV-2 infections were
192 confirmed and further analyzed. Among SARS-CoV-2-positive patients, male gender was
193 more prevalent (49% vs. 44%; $p=0.002$) and the median age was higher (49 vs. 43 years;
194 $p<0.001$) compared to those with a negative test result (**Table 1**). However, higher patient
195 age was not associated with higher SARS-CoV-2 loads (Spearman's $r=0.034$, $p=0.30$).
196 Moreover, SARS-CoV-2 was detected in 14 (4%) of 354 children compared to 916 (12%) of
197 the non-pediatric patients ($p<0.05$).

198

199 To investigate the epidemiology of CARVs and SARS-CoV-2 during the first phase of the
200 pandemic, we identified all NOPS ($n=2394$) from patients with influenza-like illness, which
201 had been tested by CARV-multiplex-NAT between January 1st (calendar week 1) and March
202 29th 2020 (calendar week 13). In 942 (39%) cases, at least one pathogen had been detected
203 including 95 with two (3.9%), and 9 with 3 (0.1%) pathogens. The weekly prevalence rates
204 for SARS-CoV-2 and CARVs revealed a fluctuating CARV activity until calendar week 7
205 followed by a steep increase in CARVs, which declined after week 10, when SARS-CoV-2
206 detection rates rose sharply (**Figure 2A**). This was also reflected in the cumulative rates
207 (**Figure 2B; histogram**) reaching 48% for SARS-CoV-2 by calendar week 13, followed by
208 rhinovirus (13%) and influenza virus (12%) (**Figure 2B; pie chart**). Restricting the analysis to
209 1816 NOPS, from which both, CARV-multiplex-NAT and SARS-CoV-2 RT-QNAT had been
210 requested, the cumulative SARS-CoV-2 detection was 17% after rhinovirus (22%) and
211 influenza virus (20%) (**Figure 2C; pie chart**). The weekly detection rates revealed that
212 SARS-CoV-2 largely replaced all other CARVs except rhinovirus (**Figure 2C**).

213

214 Unlike for SARS-CoV-2, the CARV detection rate was significantly higher in children than in
215 adults ($P<0.001$; **Table 2**). This significant effect also prevailed when SARS-CoV-2 and
216 CARV positive cases were analyzed together and when excluding rhinovirus-infected
217 cases from the analysis (**Table 2; see also below**). Analyzing the age distribution of CARV-
218 positive cases (**Figure 3**), we found higher detection rates of adenovirus, parainfluenzavirus,

219 respiratory syncytial virus, rhinovirus and influenzavirus-A/B cases in children ≤ 16 years,
220 while similar rates of human coronavirus-, metapneumovirus- and *M. pneumoniae* were
221 detected in children and adults (**Supplementary Table 3**). Moreover, adenovirus-positive
222 patients were significantly younger than patients testing positive for other CARVs or SARS-
223 CoV-2 ($P < 0.001$; **Table 3**). Among adults (1554/1816; 85.5%), no significant age differences
224 were observed for patients testing positive for any CARV, but patients being positive for
225 SARS-CoV-2 tended to be older than patients testing positive for any other CARV ($P < 0.01$;
226 **Figure 3, Supplementary Table 4**).

227

228 Among CARV positive cases, co-infections with two or three CARVs occurred in 55 (3%)
229 and five (0.3%) patients, respectively (**Table 4**). Rhinovirus and adenovirus as well as
230 rhinovirus and respiratory syncytial virus co-infections were almost exclusively found in
231 children ≤ 2 years. In 17 (0.9%) of 1816 patients (15 adults aged 30 to 93 years, 2 children),
232 SARS-CoV-2 was detected together with at least one other CARV, which consisted of a
233 single pathogen in 15 cases, namely rhinovirus ($n=5$), human coronaviruses ($n=5$),
234 parainfluenzavirus ($n=3$) and influenzavirus ($n=2$), and more than one CARV detection in 2
235 cases (**Table 4**). Overall, CARV detection was associated with a high negative predictive
236 value of 98.1% for SARS-CoV-2 infection. The negative predictive value for SARS-CoV-2
237 infection was higher in CARV-positive children (99.0%; ≤ 16 years) than adults (97.1%; > 16
238 years). Conversely, a negative multiplex-NAT result after the first detected SARS-CoV-2
239 case was associated with a rapidly increasing likelihood to be positively tested for SARS-
240 CoV-2 from 1% in calendar week 9 to 48% in calendar week 13 (**Figure 2**).

241 Discussion

242 The SARS-CoV-2 pandemic hit Europe in winter 2020, during which a number of circulating
243 CARVs are at their yearly seasonal peak including influenzavirus, respiratory syncytial virus,
244 and human coronaviruses. Our analysis from the start to the peak of the pandemic wave of
245 SARS-CoV-2 in Northwestern Switzerland has three major findings.

246 First, the early pandemic phase until calendar week 10 was dominated by winter CARVs,
247 emphasizing the importance of their rapid and accurate identification due to several reasons:
248 i) significant morbidity and mortality in vulnerable patients (very young, elderly,
249 immunocompromised) [5]; ii) specific antiviral therapy in case of influenzavirus-A/B detection;
250 iii) appropriate infection control and cohorting strategies upon hospital admission; and iv)
251 prevention of unnecessary empiric antibiotic therapy in CARV-positive patients, or treatment
252 adaptation in case of atypical bacterial agents like *M. pneumoniae* [10-13]. In this early phase,
253 CARV detection was associated with a high negative predictive value of 98.1% for SARS-
254 CoV-2 infection.

255 Second, SARS-CoV-2 almost completely replaced the seasonally circulating CARVs within
256 only 3 weeks' time. During calendar week 12 and 13, SARS-CoV-2 was practically the only
257 respiratory virus leading to a cumulative 48% runner-up position when counting all detected
258 CARVs from January 1st, 2020. This dynamic evolution was also seen when explicitly
259 analyzing NOPS from patients with respiratory illness for whom both CARV- and SARS-CoV-
260 2 testing had been requested. The weekly prevalence revealed a significant increase in SARS-
261 CoV-2 detection rates while the initially increasing CARVs were curtailed. These data suggest
262 the intriguing possibility of competing risks for host infection.

263 Third, diagnosis of SARS-CoV-2 infection was highly reliable being based on three
264 independent molecular tests. Thereby, an independent validation of the WHO-endorsed E-
265 gene was provided. Whereas respiratory panel testing is well validated and widely used in
266 tertiary care centers [5, 14, 15], the response to the SARS-CoV-2 pandemic hinges on the
267 performance of a new diagnostic test for a new viral agent, and its communication within a
268 short turn-around time. To accomplish this task, we prospectively tested all NOPS directly in

269 parallel with the commercial Roche-E-gene and our Basel-S-gene RT-QNAT. This outstanding
270 opportunity for independent test validation on more than 7600 patients demonstrated high
271 concordance of 97.5% between both assays including 825 (11%) SARS-CoV-2 infections,
272 which could be communicated without further delay to the treating physicians. Importantly,
273 comparison of the Ct-values revealed that the discordance mostly resulted from SARS-CoV-
274 2 loads at the limit of detection. Thus, discordant results became increasingly likely at very
275 low, hence limiting viral loads in the NOPS, most likely reflecting a stochastic distribution of
276 genomes in the analyte.

277

278 A limitation of our study is the dependence on the pre-analytic steps of NOPS sampling,
279 especially in the light of the natural course of SARS-CoV-2 infection. We addressed this
280 challenge through repeated instructions and video clips demonstrating the correct use of
281 personal protection equipment, validated swab sets, and defined sampling procedures in
282 dedicated hospital areas. However, late presentation at stages of more advanced disease
283 manifesting in the lower respiratory tract requires testing of respiratory samples from the lower
284 respiratory tract, while this study was restricted to the first diagnostic testing in NOPS. Early
285 testing is clinically and epidemiologically advisable in view of high viral loads detectable
286 already early in the course in exposed pre-symptomatic and in oligo-symptomatic persons [16,
287 17].

288

289 Since our diagnostic laboratory is serving both regional tertiary care centers for adults and
290 children, we examined the age distribution of SARS-CoV-2 and CARV infection. Indeed,
291 patients testing positive for adenovirus and respiratory syncytial virus were significantly
292 younger and more likely to be children below the age of 5 years, among whom SARS-CoV-2
293 infection remained rare, in line with other studies [18, 19]. Although SARS-CoV-2 positive
294 adults were older than patients testing positive for CARVs, the median age of >40 years in
295 CARV-positive patients suggests that similar adult populations were at risk for established
296 CARVs or for the novel SARS-CoV-2.

297

298 Our study also provides intriguing observations regarding the epidemiology of SARS-CoV-2
299 in its capacity to replace circulating CARVs among adults. Notably, co-infection rates of
300 CARVs with SARS-CoV-2 were rather low as reported here and by others [8], suggesting a
301 competitive infection situation. It is presently unclear whether virus properties such as higher
302 infectiousness, facilitated transmission, or increased host susceptibility are the decisive
303 factors conferring significant advantages to the novel SARS-CoV-2 in this first wave of the
304 pandemic. Regarding the infectiousness of SARS-CoV-2, our data provide independent
305 evidence for very high viral loads in the order of 1 – 100 million copies per milliliter transport
306 medium. Even if these high numbers only carry 1000-fold lower infectious units, the
307 infectious activity remains high in the patients' respiratory secretions. Notably, similarly high
308 viral loads have also been described for CARVs including influenza or respiratory syncytial
309 virus [5, 20-22]. Regarding transmission, SARS-CoV-2 is thought to behave less like
310 influenzaviruses spreading significantly by aerosols [23, 24], but rather like respiratory
311 syncytial virus spreading by droplets, contaminated surfaces and hands [25, 26]. However,
312 aerosolization of SARS-CoV-2 may also play a role, especially when associated with high-
313 velocity air streams during sneezing, singing and medical procedures [27-29].
314 Finally, increased susceptibility of the human host to infection by this novel, presumably
315 zoonotic coronavirus remains, but is a difficult to estimate factor at this time. Already the first
316 reports from China in January 2020 indicated that SARS-CoV-2 is well adapted to the
317 human host [30]. Unlike SARS-CoV-1, SARS-CoV-2 is easily transmitted from human to
318 human already before the start of symptoms, hence facilitating the pandemic spread [17, 31,
319 32]. However, SARS-CoV-2 seems to be susceptible to type-1 interferons [33], and induces
320 high amounts of interleukin-6 through excessive macrophage activation upon progression to
321 viral pneumonia, which has become a clinically relevant target of CoVID-19 treatment [34].

322

323 What could be the underlying mechanisms for an increased susceptibility to SARS-CoV-2
324 infection competitively replacing established CARVs in a mostly adult population? Hand

325 washing, social distancing and lock-down measure would be predicted to affect CARVs and
326 SARS-CoV-2 alike, but were not yet sufficiently effective to prevent the upswing of the
327 pandemic wave. We hypothesize that the decisive factors may be the differential net
328 response of the host to virus-induced unspecific innate immunity on the one hand and to
329 virus-specific adaptive immune memory on the other hand. CARV infections are known to
330 cause an innate immune response including type-1 interferons, which reduces the risk of co-
331 infection by other viruses including SARS-CoV-2 [35, 36]. Since adults have been repeatedly
332 exposed to CARVs in the past, their CARV-specific immune memory may not be high
333 enough to prevent symptomatic CARV re-infection, but is readily boosted upon re-exposure,
334 hence limiting CARV replication and the associated inflammation elicited by innate immunity.
335 We propose that thereby the semi-immune mostly adult host population becomes available
336 for SARS-CoV-2 infection. Since SARS-CoV-2 is novel having little, if any, specific immune
337 memory, its replication is prolonged, evoking pronounced inflammation, delaying infection by
338 other circulating CARVs, extending transmission periods and shifting the epidemiologic
339 curve in favor of this novel agent. This differential net response of virus-induced unspecific
340 innate immunity and virus-specific adaptive immune memory may also contribute to the
341 puzzling lower infection rates seen in small children, who typically replicate CARVs in high
342 frequency and high levels, hence interfering with SARS-CoV-2. However, CARVs may differ
343 in their propensity to interfere and may be low for rhinovirus. Indeed, 46 (60%) of 77 co-
344 infections involved rhinovirus. Although other (co-)factors cannot be excluded, our
345 hypothesis will be testable by analyzing, whether or not vaccines to CARVs and/or to SARS-
346 CoV-2 change this competitive epidemiologic risk. Possibly, CARV interference will be
347 reduced during the summer months putting younger age populations at risk for the pandemic
348 SARS-CoV-2.

349

350 In conclusion, circulating CARVs were dominant during the first phase of the CoVID-19
351 pandemic, but rapidly replaced within 2 weeks by SARS-CoV-2. A comprehensive testing
352 strategy covering SARS-CoV-2 and CARVs is central to infection control and clinical

353 management. Epidemiologic determinants of the competitive infection risk between
354 established CARVs and the novel SARS-CoV-2 require further studies including unspecific
355 innate immune interference and virus-specific adaptive immune memory.

356

357 **Main Body Word Count: 3212**

358 **Acknowledgements**

359 We thank the biomedical technicians of the Clinical Virology Division and the Clinical
360 Bacteriology and Mycology Division, Laboratory Medicine, University Hospital Basel, Basel,
361 Switzerland for expert help and assistance.

362 **Figure Legend**

363 **Figure 1. Comparison of cycling thresholds in the S-gene, E-gene and N-gene RT-**
364 **QNATs and SARS-CoV-2 loads.**

365 NOPS were submitted for routine testing with the S-gene and E-gene RT-QNATs (n=7663).

366 Samples with concordant positive or discordant results were subsequently tested with the in-
367 house N-gene RT-QNAT.

368 A. Cycling thresholds of concordant positive and discordant samples are displayed
369 (median, 25th and 75th percentiles; n=7663).

370 B. SARS-CoV-2 loads and number of cases determined with the S-gene RT-QNAT in
371 positive samples (median, 25th and 75th percentiles; n=927).

372

373 **Figure 2. SARS-CoV-2 and CARV epidemiology during the beginning of the epidemic**
374 **spread from January to March 2020.**

375 HAdV, human adenoviruses; HCoV, human coronavirus (-229E, -OC43, -NL63, and -HKU1);

376 IV-A/B, influenza virus A and B; HMPV, human metapneumovirus; HPIV, human

377 parainfluenzavirus (1 to 4); HRV, human rhinovirus; HRSV, human respiratory syncytial

378 virus; M. pne, Mycoplasma pneumoniae; SARS-CoV-2, severe acute respiratory syndrome

379 coronavirus.

380 A. Weekly SARS-CoV-2 (n=8592) and CARV (n=2394) prevalence in symptomatic
381 children and adults.

382 B. Weekly prevalence of cumulated SARS-CoV-2 (n=8592) and CARV (N=2394) cases
383 in symptomatic children and adults (bar chart), cumulated SARS-CoV-2 and CARV
384 cases by calendar week 13 (pie chart).

385 C. Weekly SARS-CoV-2 and CARV prevalence in NOPS tested in parallel (n=1816),
386 cumulated SARS-CoV-2 and CARV cases by calendar week 13 (pie chart).

387 **Figure 3. Age distribution of CARV and SARS-CoV-2 positive patients.**

388 NOPS were analyzed in parallel for different CARVs with multiplex NAT and SARS-CoV-2
389 with the RT-QNAT assays. Patient age of CARV or SARS-CoV-2 positive patients is displayed
390 (median, 25th and 75th percentiles; n=1816), and compared using Mann–Whitney U test (Table
391 3; Supplementary Table 4).

392 **References**

- 393 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China,
394 2019. *New Engl J Med* **2020**; 382: 727.
- 395 2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus
396 of probable bat origin. *Nature* **2020**; 579: 270.
- 397 3. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species
398 Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it
399 SARS-CoV-2. *Nat Microbiol* **2020**; 5: 536.
- 400 4. WHO. Coronavirus disease (COVID-19) Situation Report–119. World Health Organization
401 **2020**.
- 402 5. Ison MG, Hirsch HH. Community-Acquired Respiratory Viruses in Transplant Patients:
403 Diversity, Impact, Unmet Clinical Needs. *Clin Microbiol Rev* **2019**; 32: e00042-19.
- 404 6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
405 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From
406 the Chinese Center for Disease Control and Prevention. *JAMA* **2020**; doi:
407 10.1001/jama.2020.2648.
- 408 7. Nicastri E, D'Abramo A, Faggioni G, et al. Coronavirus disease (COVID-19) in a
409 paucisymptomatic patient: epidemiological and clinical challenge in settings with limited
410 community transmission, Italy, February 2020. *Eur Surveill* **2020**; 25: 2000230.
- 411 8. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2
412 and Other Respiratory Pathogens. *JAMA* **2020**; 323:2085.
- 413 9. Leuzinger K, Naegele K, Schaub S, Hirsch HH. Quantification of plasma BK polyomavirus
414 loads is affected by sequence variability, amplicon length, and non-encapsidated viral DNA
415 genome fragments. *J Clin Virol* **2019**; 121: 104210.
- 416 10. Beckmann C, Hirsch HH. Comparing Luminex NxTAG-Respiratory Pathogen Panel and
417 RespiFinder-22 for multiplex detection of respiratory pathogens. *J Med Virol* **2016**; 88: 1319.
- 418 11. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious
419 Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and
420 Institutional Outbreak Management of Seasonal Influenzaa. *Clin Infect Dis* **2019**; 68: 1.

- 421 12. Krantz EM, Zier J, Stohs E, et al. Antibiotic Prescribing and Respiratory Viral Testing for
422 Acute Upper Respiratory Infections Among Adult Patients at an Ambulatory Cancer Center.
423 Clin Infect Dis **2020**; 70: 1421.
- 424 13. Dierig A, Hirsch HH, Decker ML, Bielicki JA, Heininger U, Ritz N. Mycoplasma pneumoniae
425 detection in children with respiratory tract infections and influence on management - a
426 retrospective cohort study in Switzerland. Acta paediatrica **2020**; 109: 375.
- 427 14. Charlton CL, Babady E, Ginocchio CC, et al. Practical Guidance for Clinical Microbiology
428 Laboratories: Viruses Causing Acute Respiratory Tract Infections. Clin Infect Dis **2019**; 32: 1.
- 429 15. Hirsch HH. Spatiotemporal Virus Surveillance for Severe Acute Respiratory Infections in
430 Resource-limited Settings: How Deep Need We Go? Clin Infect Dis **2019**; 68: 1126.
- 431 16. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of
432 Infected Patients. New Engl J Med **2020**; 382: 1177.
- 433 17. Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2
434 infection. Lancet Infect Dis **2020**; 20: 410.
- 435 18. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
436 coronavirus in Wuhan, China. Lancet (London, England) **2020**; 395: 497.
- 437 19. Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The epidemiological
438 characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China, 2020.
439 Vol. 2. China CDC Weekly, **2020**; 113.
- 440 20. Chemaly RF, Dadwal SS, Bergeron A, et al. A phase 2, randomized, double-blind, placebo-
441 controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory
442 tract infection in hematopoietic-cell transplant recipients. Clin Infect Dis **2019**; ciz1166
- 443 21. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with
444 hematological diseases: single-center study and review of the literature. Clin Infect Dis **2008**;
445 46: 402.
- 446 22. Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after
447 allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis **2009**; 11: 100.
- 448 23. Cowling BJ, Ip DK, Fang VJ, et al. Aerosol transmission is an important mode of influenza A
449 virus spread. Nat Commun **2013**; 4: 1935.

- 450 24. Tellier R. Review of aerosol transmission of influenza A virus. *Emerg Infect Dis* **2006**; 12:
451 1657.
- 452 25. Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus infection:
453 comparison of reverse transcription-PCR to viral culture and serology in adults with
454 respiratory illness. *J Clin Microbiol* **2002**; 40: 817.
- 455 26. Gerna G, Campanini G, Rognoni V, et al. Correlation of viral load as determined by real-time
456 RT-PCR and clinical characteristics of respiratory syncytial virus lower respiratory tract
457 infections in early infancy. *J Clin Virol* **2008**; 41: 45.
- 458 27. Zhan M, Qin Y, Xue X, Zhu S. Death from Covid-19 of 23 Health Care Workers in China. *New*
459 *Engl J Med* **2020**; 382: 2267.
- 460 28. Ong SWX, Tan YK, Chia PY, et al. Air, Surface Environmental, and Personal Protective
461 Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
462 CoV-2) From a Symptomatic Patient. *JAMA* **2020**; 323: 1610.
- 463 29. Hamner L, Dubbel P, Capron I, et al. High SARS-CoV-2 Attack Rate Following Exposure at a
464 Choir Practice - Skagit County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep*
465 **2020**; 69: 606.
- 466 30. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
467 Coronavirus-Infected Pneumonia. *New Engl J Med* **2020**; 382: 1199.
- 468 31. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19.
469 *JAMA* **2020**; 323: 1406.
- 470 32. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and
471 Transmission in a Skilled Nursing Facility. *New Engl J Med* **2020**; 382: 2081.
- 472 33. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a
473 potential treatment against COVID-19. *Antivir Res* **2020**; 178: 104791.
- 474 34. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely
475 correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients.
476 *Clin Infect Dis* **2020**; ciaa449.
- 477 35. Compagno F, Braunacker-Mayer L, Khanna N, et al. Comparing viral respiratory tract
478 infections in symptomatic children and adults: Multiplex NAT from 2010 - 2015 (EP0641).
479 *ECCMID 2017. Vienna, Austria* **2017**.

- 480 36. Mesev EV, LeDesma RA, Ploss A. Decoding type I and III interferon signalling during viral
481 infection. *Nat Microbiol* **2019**; 4: 914.

Table 1. Patients' demographics of NOPS tested for SARS-CoV-2 between calendar week 11 and 13 (Mann–Whitney U test; n=7663).

		All	SARS-CoV-2 positive	SARS-CoV-2 negative	p-value
Patients' Demographics	Patients (N,%)	7663	930 (12%)	6733 (88%)	-
	Age (median, IQR)	43	49	43	
		25 th : 31	25 th : 34	25 th : 30	p<0.001
		75 th : 58	75 th : 62	75 th : 57	
		IQR: 27	IQR: 28	IQR: 27	
	Gender (male, %)	3407 (44%)	458 (49%)	2949 (44%)	P=0.002
	Pediatric patients (≤16 years)	354 (5%)	14 (4%)	340 (96%)	p<0.001
Primary Care		5697 (74%)	774 (83%)	4923 (73%)	-
Secondary or Tertiary Care		1966 (26%)	156 (17%)	1810 (27%)	-
	Medical Care Unit	136 (7%)	11 (7%)	125 (7%)	-
	Intensive Care Unit	67 (3%)	8 (5%)	59 (3%)	-
	Pneumology Unit	45 (2%)	1 (1%)	44 (2%)	-

Table 2. Comparison of SARS-CoV-2 and any CARV infection in adult and pediatric patients using Mann–Whitney U test (n=1816; excluding human rhinovirus only cases n=1671).

Pathogen	Testresult	Age		p-value
		≤16 years	>16 years	
SARS-CoV-2	Positive	5 (2%)	143 (9%)	P<0.001
	Negative	257 (98%)	1411 (91%)	
Any CARV ¹	Positive	166 (63%)	479 (31%)	P<0.001
	Negative	96 (37%)	1075 (69%)	
SARS-CoV-2 or any CARV	Positive	169 (65%)	606 (39%)	P<0.001
	Negative	93 (35%)	948 (61%)	
SARS-CoV-2 or CARV (excluding rhinovirus)	Positive	127 (65%)	503 (39%)	P<0.001
	Negative	93 (35%)	948 (61%)	

¹Any CARV includes: human adenoviruses, human coronavirus (-229E, -OC43, -NL63, and -HKU1), influenza virus A and B, human metapneumovirus, human parainfluenzavirus (1 to 4), human rhinovirus, human respiratory syncytial virus and the atypical bacterial agent *M. pneumoniae*

Table 3. Pairwise comparison of patient age in SARS-CoV-2 or CARV positive patients (Mann–Whitney U test; brackets indicate the p-value after Bonferroni correction; n=1816).

	HAdV	HPIV	HRSV	HRV	IV-A/B	HCoV	HMPV	M.pne	SARS-CoV-2
HAdV		0.05 [0.4]	0.2 [1]	0.0007 [0.005]	7.9e-08 [6.4e-07]	1.3e-07 [1.0e-06]	5.4e-07 [4.3e-06]	3.9e-05 [0.0003]	1.7e-14 [1.4e-13]
HPIV	0.05 [0.4]		0.7 [1]	0.5 [1]	0.03 [0.2]	0.02 [0.2]	0.02 [0.1]	0.05 [0.4]	2.4e-05 [0.0002]
HRSV	0.2 [1]	0.7 [1]		0.08 [0.6]	0.0004 [0.003]	0.0003 [0.003]	0.0002 [0.001]	0.01 [0.08]	9.9e-11 [7.9e-10]
HRV	0.0007 [0.005]	0.5 [1]	0.08 [0.6]		0.005 [0.04]	0.003 [0.02]	0.0007 [0.006]	0.06 [0.5]	5.3e-14 [4.2e-13]
IV-A/B	7.9e-08 [6.4e-07]	0.03 [0.2]	0.0004 [0.003]	0.005 [0.04]		0.4 [1]	0.09 [0.7]	0.7 [1]	1.2e-09 [9.9e-09]
HCoV	1.3e-07 [1.0e-06]	0.02 [0.2]	0.0003 [0.003]	0.003 [0.02]	0.4 [1]		0.3 [1]	0.9 [1]	0.3 [1]
HMPV	5.4e-07 [4.3e-06]	0.02 [0.1]	0.0002 [0.001]	0.0007 [0.006]	0.09 [0.7]	0.3 [1]		0.4 [1]	0.02 [0.1]
M.pne	3.9e-05 [0.0003]	0.05 [0.4]	0.01 [0.08]	0.06 [0.5]	0.7 [1]	0.9 [1]	0.4 [1]		0.9 [1]
SARS-CoV-2	1.7e-14 [1.4e-13]	2.4e-05 [0.0002]	9.9e-11 [7.9e-10]	5.3e-14 [4.2e-13]	1.2e-09 [9.9e-09]	0.3 [1]	0.02 [0.1]	0.9 [1]	

	P>0.05
	P<0.05

HAdV, human adenoviruses; HCoV, human coronavirus (-229E, -OC43, -NL63, and -HKU1);

IV-A/B, influenza virus A and B; HMPV, human metapneumovirus; HPIV, human parainfluenzavirus (1 to 4);

HRV, human rhinovirus; HRSV, human respiratory syncytial virus; M. pne, Mycoplasma pneumoniae;


SARS-CoV-2, severe acute respiratory syndrome coronavirus

Table 4. Patients with more than one positive SARS-CoV-2 or CARV detection (n=1816).


CARVs detected	Number of patients	Age ≤2 years	Age ≤5 years	Age ≤16 years	Age >16 years
SARS-CoV-2 and HCoV	5	-	-	-	5
SARS-CoV-2 and HRV	5	-	1	1	4
SARS-CoV-2 and HPIV	3	-	-	-	3
SARS-CoV-2 and IV-A	2	-	-	-	2
SARS-CoV-2 and HRV and HAdV	1	-	-	-	1
SARS-CoV-2 and HRV and HRSV and HPIV	1	-	1	1	-
HRV and HAdV	11	8	10	10	1
HRV and HCoV	6	2	2	3	3
HRV and IV-A/B	5	1	1	2	3
HRV and HRSV	5	3	4	4	1
HRV and HPIV	3	-	2	2	1
HRV and HMPV	2	1	1	1	1
HRV and M. pne	1	-	-	-	1
HRV and B. para	1	-	1	1	-
HRV and HCoV and IV-A/B	1	-	-	1	-
HRV and HCoV and HAdV	1	-	1	1	-
HRV and HRSV and IV-A/B	1	-	1	1	-
HRV and HPIV and HAdV	1	-	-	1	-
HCoV and IV-A/B	3	-	-	-	3
HCoV and HRSV	3	2	2	2	1
HCoV and HPIV	2	-	-	-	2
HCoV and HMPV	2	1	1	1	1
HCoV and HAdV	2	1	2	2	-
HCoV and HMPV and M. pne	1	-	1	1	-
HAdV and HRSV	2	-	1	1	1
HAdV and IV-A/B	1	-	-	-	1
HAdV and B. para	1	-	-	1	-
HAdV and M. pne	1	-	-	-	1
HAdV and HMPV	1	1	1	1	-
IV-A/B and HRSV	2	1	1	2	-
IV-A/B and HMPV	1	-	-	-	1
Total	77	21	34	40	37


B. per, Bordetella pertussis; B. para, Bordetella parapertussis; HAdV, human adenoviruses; HCoV, human coronavirus (-229E, -OC43, -NL63, and -HKU1); hMPV, human metapneumovirus; HPIV, human parainfluenzavirus (1 to 4); HRV, human rhinovirus; IV-A/B, influenza virus A and B; M. pne, Mycoplasma pneumoniae; SARS-CoV-2, severe acute respiratory syndrome coronavirus

Figure 1
A





B



B

C






Table S1. Forward primers, reverse primers and probes of the SARS-CoV-2 RT-QNATs.

Gene	Primer/Probe	Sequence (5'→ 3')	Position ¹
Spike glycoprotein (Basel-SCoV2-S-111bp)	Forward primer	GGTTATCTTCAACCTAGGAC	22364 - 22383
	Reverse primer	ATTTCAACGTACACTTTGTT	22475 - 22456
	Probe	TGTAGACTGTGCACTTGACCCTCTCTC	22426 - 22452
Nucleocapsid (Basel-SCoV2-N-98bp)	Forward primer	ATCGGTAATTATACAGTTTCC	28119 - 28139
	Reverse primer	AGTCTTCATAGAACGAACAA	28215 - 28196
	Probe	TGCCAGGAACCTAAATTGGGTAGTCT	28161 - 28186

¹ Position according to SARS-CoV-2 isolate Wuhan-Hu-1 (acc. no. NC_045512.2)

Table S2. Frequency of single nucleotide polymorphisms in the laboratory-developed SARS-CoV-2 spike glycoprotein (Basel-SCoV2-S-111bp) and nucleocapsid (Basel-SCoV2-N-98bp) RT-QNAT target regions.

Gene	Position ¹	SNP ²	Frequency (%)		
			±150bp ³	±100bp ³	±5bp ³
Spike glycoprotein (Basel-SCoV2-S-111bp)	22224	C → G	0.03% ⁴	-	-
	22303	T → G	0.03% ⁴	0.03% ⁴	-
	22432	C → T	0.03% ⁵	0.03% ⁵	0.03% ⁵
Nucleocapsid (Basel-SCoV2-S-98bp)	28077	G → C	0.1% ⁴	0.1% ⁴	-
	28144	T → C	0.3% ⁶	0.3% ⁶	0.3% ⁶

¹ Position according to SARS-CoV-2 isolate Wuhan-Hu-1 (acc. no. NC_045512.2)

² Single nucleotide polymorphism (SNP) and frequency among 3323 SARS-CoV-2 (taxid: 2697049) spike glycoprotein-gene and nucleocapsid-gene GenBank and GISAID sequences (accessed on 20th of April 2020) compared to SARS-CoV-2 as reference genome (acc. no. NC_045512.2).

³ RT-QNAT target region ±150bp, ±100bp and ±5bp

⁴ SNP outside the RT-QNAT target region

⁵ SNP in the probe-binding site

⁶ SNP in the RT-QNAT target region, but not in a primer/probe-binding site

Table S3. Comparison of SARS-CoV-2 and any CARV infection and the age distribution of adult and pediatric patients using Mann–Whitney U test (n=1816).

Pathogen	≤16 years (N=262)		>16 years (N=1554)		p-value
	Number of positive cases	Age	Number of positive cases	Age	
		Distribution		Distribution	
HAdV	27 (10%)	Median: 2	16 (1%)	Median: 40	P<0.001
		25 th : 1		25 th : 34	
		75 th : 4		75 th : 51	
HPIV	9 (3%)	IQR: 3	11 (1%)	IQR: 17	P=0.02
		Median: 4		Median: 50	
		25 th : 3		25 th : 24	
HRSV	29 (11%)	75 th : 6	36 (2%)	75 th : 62	P<0.001
		IQR: 3		IQR: 39	
		Median: 1		Median: 42	
HRV	71 (27%)	25 th : 1	119 (8%)	25 th : 32	P<0.001
		75 th : 4		75 th : 66	
		IQR: 3		IQR: 34	
IV-A/B	34 (13%)	Median: 3	135 (9%)	Median: 44	P=0.03
		25 th : 1.5		25 th : 36	
		75 th : 4.5		75 th : 67	
HCoV	18 (7%)	IQR: 3.0	100 (6%)	IQR: 31	P=0.79
		Median: 6		Median: 46	
		25 th : 3		25 th : 32	
HMPV	16 (6%)	75 th : 9	63 (4%)	75 th : 62	P=0.13
		IQR: 6		IQR: 30	
		Median: 3		Median: 49	
M. pne	3 (1%)	25 th : 1	20 (1%)	25 th : 34	P=0.85
		75 th : 4		75 th : 63	
		IQR: 3		IQR: 29	
SARS-CoV-2	5 (2%)	Median: 4	143 (9%)	Median: 58	P<0.001
		25 th : 1		25 th : 38	
		75 th : 4		75 th : 76	
		IQR: 3		IQR: 38	
		Median: 10		Median: 47	
		25 th : 7		25 th : 38	
		75 th : 11		75 th : 55	
		IQR: 4		IQR: 18	
		Median: 2		Median: 61	
		25 th : 1		25 th : 43	
		75 th : 3		75 th : 75	
		IQR: 2		IQR: 32	

HAdV, human adenoviruses; HCoV, human coronavirus (-229E, -OC43, -NL63, and -HKU1);

IV-A/B, influenza virus A and B; HMPV, human metapneumovirus; HPIV, human parainfluenzavirus (1 to 4);

HRV, human rhinovirus; HRSV, human respiratory syncytial virus; M. pne, Mycoplasma pneumoniae;

SARS-CoV-2, severe acute respiratory syndrome coronavirus

Table S4. Pairwise comparison of patient age in SARS-CoV-2 or CARV positive adults of >16 years (Mann–Whitney U test; brackets indicate the p-value after Bonferroni correction; n=1554).

	HAdV	HPIV	HRSV	HRV	IV-A/B	HCoV	HMPV	M.pne	SARS-CoV-2
HAdV		0.7 [1]	0.5 [1]	0.2 [1]	0.3 [1]	0.2 [1]	0.02 [0.2]	0.4 [1]	0.001 [0.01]
HPIV	0.7 [1]		0.6 [1]	0.4 [1]	0.6 [1]	0.6 [1]	0.2 [1]	0.9 [1]	0.07 [0.5]
HRSV	0.5 [1]	0.6 [1]		0.5 [1]	0.9 [1]	0.9 [1]	0.08 [0.6]	0.9 [1]	0.001 [0.01]
HRV	0.2 [1]	0.4 [1]	0.5 [1]		0.4 [1]	0.6 [1]	0.06 [0.4]	0.6 [1]	0.001 [0.01]
IV-A/B	0.3 [1]	0.6 [1]	0.9 [1]	0.4 [1]		0.8 [1]	0.01 [0.08]	0.7 [1]	1.5e-05 [0.0001]
HCoV	0.2 [1]	0.6 [1]	0.9 [1]	0.6 [1]	0.8 [1]		0.02 [0.2]	0.6 [1]	0.0002 [0.002]
HMPV	0.02 [0.2]	0.2 [1]	0.08 [0.6]	0.06 [0.4]	0.01 [0.08]	0.02 [0.2]		0.04 [0.3]	0.7 [1]
M.pne	0.4 [1]	0.9 [1]	0.9 [1]	0.6 [1]	0.7 [1]	0.6 [1]	0.04 [0.3]		0.005 [0.04]
SARS-CoV-2	0.001 [0.01]	0.07 [0.5]	0.001 [0.01]	0.001 [0.01]	1.5e-05 [0.0001]	0.0002 [0.002]	0.7 [1]	0.005 [0.04]	

	P>0.05
	P<0.05


HAdV, human adenoviruses; HCoV, human coronavirus (-229E, -OC43, -NL63, and -HKU1);

IV-A/B, influenza virus A and B; HMPV, human metapneumovirus; HPIV, human parainfluenzavirus (1 to 4);


HRV, human rhinovirus; HRSV, human respiratory syncytial virus; M. pne, Mycoplasma pneumoniae;

SARS-CoV-2, severe acute respiratory syndrome coronavirus

A Complete genome sequences of human coronaviruses



B Spike glycoprotein gene sequences of human coronaviruses



C Nucleocapsid gene sequences of human coronaviruses




Figure S1. Phylogenetic analysis using complete SARS-CoV-2 genome sequences, the S-gene and N-gene sequences.

Divergences were estimated by the Jukes-Cantor method and neighbor-joining trees were constructed with the CLC Genomic Workbench software.

- A. Phylogenetic analysis of complete SARS-CoV-2 genome sequences of 29'900 nucleotides (nt) in length available in the NCBI-GenBank and GISAID database (accessed on 20th of April; n=3323).
- B. Phylogenetic analysis of the S-gene region of 3'822 nt (corresponds to nucleotide positions 21563 to 25384 in the SARS-CoV-2 reference genome [acc. no. NC_045512.2]; n=3323).
- C. Phylogenetic analysis of the N-gene region of 366 nt (corresponds to nucleotide positions 27894 to 28259 in the SARS-CoV-2 reference genome [acc. no. NC_045512.2]; n=3323).

Figure S1. Phylogenetic analysis using complete SARS-CoV-2 genome sequences, the S-gene and N-gene sequences.

Divergences were estimated by the Jukes-Cantor method and neighbor-joining trees were constructed with the CLC Genomic Workbench software.

- A. Phylogenetic analysis of complete SARS-CoV-2 genome sequences of 29'900 nucleotides (nt) in length available in the NCBI-GenBank and GISAID database (accessed on 20th of April; n=3323).
- B. Phylogenetic analysis of the S-gene region of 3'822 nt (corresponds to nucleotide positions 21563 to 25384 in the SARS-CoV-2 reference genome [acc. no. NC_045512.2]; n=3323).
- C. Phylogenetic analysis of the N-gene region of 366 nt (corresponds to nucleotide positions 27894 to 28259 in the SARS-CoV-2 reference genome [acc. no. NC_045512.2]; n=3323).




Figure S2. SARS-CoV-2 testing flowchart.

NOPS were tested in parallel with the in-house S-gene and the commercial E-gene RT-QNATs (n=7663). Samples with concordant positive or discordant results were subsequently tested with the in-house N-gene RT-QNAT. pos, positive; neg, negative.